Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch
05 Sep 2024
// BUSINESSWIRE
27 Jun 2024
// BUSINESSWIRE
23 May 2024
// BUSINESSWIRE
30 Jan 2024
// BUSINESSWIRE
20 Apr 2023
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/abdera-skyrockets-out-stealth-142-million-biotechs-radiopharmaceutical-ambitions-take
20 Apr 2023
// BUSINESSWIRE
Details:
ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of large cell neuroendocrine carcinoma.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2024
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abdera Gets FDA Orphan Drug Designation For ABD-147 in Neuroendocrine Carcinoma
Details : ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of large cell neuroendocrine carcinoma.
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 05, 2024
Details:
ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225, it is being investigated in extensive stage small cell lung cancer expressing DLL3.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abdera Therapeutics Gets FDA Fast Track Designation for ABD-147 in Small Cell Lung Cancer
Details : ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225, it is being investigated in extensive stage small cell lung cancer expressing DLL3.
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 27, 2024
Details:
ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2024
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Details : ABD-147 is the first precision radiopharmaceutical therapy targeting DLL3, being advanced for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma.
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 23, 2024
Details:
The financing will be used to engineer and advance best-in-class antibody-based radiopharmaceuticals, including ABD-147, for cancer, by leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals.
Lead Product(s): ABD-147
Therapeutic Area: Oncology Brand Name: ABD-147
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Versant Ventures
Deal Size: $142.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2023
Lead Product(s) : ABD-147
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Versant Ventures
Deal Size : $142.0 million
Deal Type : Financing
Details : The financing will be used to engineer and advance best-in-class antibody-based radiopharmaceuticals, including ABD-147, for cancer, by leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceu...
Brand Name : ABD-147
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 20, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?